Schulman Claude
Department of Urology, University of Brussels, Belgium.
BJU Int. 2007 Jul;100 Suppl 1:6-11. doi: 10.1111/j.1464-410X.2007.6976.x.
To understand the attitudes of patients with prostate cancer toward the disease in general and to the use of hormone therapy as treatment; to assess unmet needs in the management of prostate cancer; and to gauge patient receptivity to a potential 6-month formulation of a luteinizing hormone-releasing hormone (LHRH) agonist.
Face-to-face interviews, lasting 50 min on average, were conducted during January and February 2007 with 200 European men who had been diagnosed with prostate cancer.
Most patients were very satisfied with their physician, particularly with specialists, with 94% of men being satisfied with their expertise and 67% fully trusting the recommended treatment. Therapeutic efficacy was considered the most crucial aspect of treatment, although maintaining their lifestyle during treatment was also considered important (83% of patients). In all, 67% of patients believed that consideration should be given to lifestyle needs when selecting treatment; however, over half (55%) had never raised lifestyle issues with their physicians. Most patients would prefer fewer injections, with 68% preferring 6-monthly injections over 3- or 1-monthly depots. Perceived advantages of 6-monthly injections include less discomfort/pain, more quality of life, fewer reminders of the disease and more ability to undertake activities without restriction.
Patients with prostate cancer are generally very satisfied with their physicians and the information they receive, yet find it difficult to communicate their lifestyle needs. Most patients would prefer 6-monthly LHRH agonist therapy due to the many advantages associated with fewer injections, including its efficacy in reducing testosterone levels. Improving patients' willingness to raise lifestyle issues with their physicians, providing more effective patient-physician communication and less frequent injections might assist in achieving both optimal control of testosterone and optimal management of prostate cancer.
了解前列腺癌患者对该疾病总体的态度以及对使用激素疗法作为治疗手段的态度；评估前列腺癌管理中未满足的需求；并衡量患者对促黄体生成激素释放激素（LHRH）激动剂潜在6个月剂型的接受程度。
2007年1月和2月期间，对200名被诊断患有前列腺癌的欧洲男性进行了平均时长50分钟的面对面访谈。
大多数患者对其医生，尤其是专科医生非常满意，94%的男性对医生的专业知识感到满意，67%的患者完全信任推荐的治疗方法。治疗效果被认为是治疗最关键的方面，不过在治疗期间维持生活方式也被认为很重要（83%的患者）。总体而言，67%的患者认为在选择治疗方法时应考虑生活方式需求；然而，超过半数（55%）的患者从未向医生提及过生活方式相关问题。大多数患者希望减少注射次数，68%的患者更倾向于每6个月注射一次，而非每3个月或1个月注射一次。每6个月注射一次的感知优势包括不适/疼痛更少、生活质量更高、对疾病的提醒更少以及进行活动时受限更少。
前列腺癌患者总体上对其医生及所获得的信息非常满意，但发现难以表达他们的生活方式需求。大多数患者更倾向于每6个月进行一次LHRH激动剂治疗，因为减少注射次数有诸多优势，包括其在降低睾酮水平方面的疗效。提高患者向医生提及生活方式问题的意愿、提供更有效的医患沟通以及减少注射频率，可能有助于实现睾酮的最佳控制和前列腺癌的最佳管理。
